,i #aadth ,,congress #ast ,session ,h4 ,r4 #acec ,,in ,,the ,,house ,,of ,,representatives ,march #ac1 #bjae ,mr4 ,bilirakis 7for himself1 ,mr4 ,connolly1 ,mr4 ,israel1 and ,mr4 ,griffith7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to extend the period of exclusivity with respect to certain drugs1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,promoting ,access for ,treatments ,ideal in ,enhancing ,new ,therapies ,act of #bjae1 or the ,,patient ,act of #bjae4 #b4 ,extended exclusivity period for certain new drug applications and abbreviated new drug applications 7a7 ,new drug applications ,section #eje7;c77#c77;,e7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;c77#c77;,e77 is amended by adding at the end the following new clause3 7vi7 ,with respect to an application described in clause 7iii7 or a supplement to an application described in clause 7iv71 the three-year period specified in such clause shall be extended for an additional #bd-month period if the person submitting such application or supplement provides documentation to the ,secretary demonstrating that-- 7,i7 the new clinical investigations essential to the approval of the application or supplement and conducted or sponsored by the person submitting the application or supplement support the approval of a new indication or use for the drug that is the subject of the application or supplement2 or 7,,ii7 the drug that is the subject of the application or supplement has been reformulated or redesigned so that the drug can reasonably 7as determined by the ,secretary in consultation with the person submitting such application or supplement7 be expected-- 7aa7 to promote greater patient adherence to an approved treatment regime relative to the previously approved formulation or design of the drug2 7bb7 to reduce the public-health risks associated with the drug relative to the previously approved formulation or design of the drug2 7cc7 to reduce the manner or extent of side effects or adverse events associated with the previously approved formulation or design of the drug2 7dd7 to provide systemic benefits to the health-care system relative to the previously approved formulation or design of the drug2 or 7ee7 to provide other patient benefits that are comparable to the benefits described in items 7aa7 through 7dd74 4 7b7 ,abbreviated new drug applications ,section #eje7;j77#e77;,f7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;j77#e77;,f77 is amended by adding at the end the following new clause3 7vi7 ,with respect to an application described in clause 7iii7 or a supplement to an application described in clause 7iv71 the three-year period specified in such clause shall be extended for an additional #bd-month period if the person submitting such application or supplement provides documentation to the ,secretary demonstrating that-- 7,i7 the new clinical investigations essential to the approval of the application or supplement and conducted or sponsored by the person submitting the application or supplement support the approval of a new indication or use for the drug that is the subject of the application or supplement2 or 7,,ii7 the drug that is the subject of the application or supplement has been reformulated or redesigned so that the drug may reasonably 7as determined by the ,secretary in consultation with the person submitting such application or supplement7 be expected-- 7aa7 to promote greater patient adherence to an approved treatment regime relative to the previously approved formulation or design of the drug2 7bb7 to reduce the public-health risks associated with the drug relative to the previously approved formulation or design of the drug2 7cc7 to reduce the manner or extent of side effects or adverse events associated with the previously approved formulation or design of the drug2 7dd7 to provide systemic benefits to the health-care system relative to the previously approved formulation or design of the drug2 or 7ee7 to provide other patient benefits that are comparable to the benefits described in items 7aa7 through 7dd74 4 7c7 ,regulations ,not later than #ahj days after the date of the enactment of this ,act1 the ,secretary of ,health and ,human ,services shall promulgate final regulations to carry out the amendments made by this section1 including regulations establishing a process under which the ,secretary consults with persons who claim eligibility for the extension provided by clause 7vi7 of subsection 7c77#c77;,e7 or 7j77#e77;,f7 of section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 7as added by subsections 7a7 and 7b77 regarding how the drug that is the subject of such a claim may reasonably be expected to provide a benefit described in item 7aa71 7bb71 7cc71 7dd71 or 7ee7 of clause 7vi77,,ii7 of each such subsection4